Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • FOXM1, ceRNA Networks, and ERα in Female Lung Adenocarcinoma

    2026-05-13

    Dissecting FOXM1 and Estrogen Receptor Networks in Female Lung Adenocarcinoma

    Study Background and Research Question

    Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality globally, with notably high incidence rates among females. Despite significant advances in targeted therapies, the survival rate for LUAD lingers at approximately 16% (source: paper). The molecular heterogeneity of LUAD, especially in female patients, underscores the urgent need for novel biomarkers and a deeper mechanistic understanding of disease progression. The present study by Zhang et al. addresses this gap by investigating the role of the transcription factor FOXM1 and its interaction with non-coding RNAs and estrogen receptor signaling, aiming to elucidate regulatory networks that could inform prognosis and therapeutic response in female LUAD.

    Key Innovation from the Reference Study

    The central innovation of this work lies in its integrative, multi-omics approach—combining transcriptomic data, bioinformatics, and experimental validation—to construct and verify a competitive endogenous RNA (ceRNA) network centered on FOXM1 and estrogen receptor 1 (ERα). By bridging gene expression profiling with clinical and immunological correlation analyses, the study not only identifies FOXM1 as a biomarker but also contextualizes its role within a regulatory axis involving miRNAs (notably has-miR-204-5p) and estrogen receptor signaling. This network provides mechanistic insight into LUAD progression and differential immunotherapeutic sensitivities among patient subgroups (source: paper).

    Methods and Experimental Design Insights

    The research team implemented a comprehensive workflow combining large-scale data mining with in vitro validation:
    • Transcriptomic Data Integration: Data from GDC TCGA and GEO were leveraged for differential gene expression and survival analyses. FOXM1 was prioritized based on its elevated expression in LUAD and its association with poor clinical outcomes.
    • ceRNA Network Construction: miRNA target predictions were performed via miRDB, miRTarBase, and TargetScan. Co-expression analysis enabled the assembly of a ceRNA network comprising DGCR5 (lncRNA), has-miR-204-5p, FOXM1, and ERα.
    • Experimental Validation: The physical and regulatory interactions among constituents were verified in vitro, focusing on the impact of FOXM1 knockdown on LUAD cell proliferation and apoptosis. The relationship between FOXM1 and estrogen receptor 1 was probed using gene expression and protein interaction assays.
    • Immunological Profiling: Tumor mutational burden (TMB) and immune cell infiltration were analyzed to assess the link between FOXM1 expression and immunotherapy sensitivity.

    Protocol Parameters

    • assay | differential expression analysis | FPKM/RPKM normalization | bulk tissue RNA-seq from LUAD vs. normal | enables robust detection of FOXM1 overexpression | paper
    • assay | survival correlation meta-analysis | multivariate Cox regression | 5-year overall survival in LUAD | quantifies prognostic value of FOXM1 | paper
    • assay | miRNA target validation | luciferase reporter, RT-qPCR | cell lines (A549, H1975) | confirms miR-204-5p regulation of FOXM1 | paper
    • assay | cell proliferation/apoptosis assay | siRNA knockdown | LUAD cell lines | measures functional impact of FOXM1 suppression | paper
    • assay | immune infiltration scoring | CIBERSORT, GSEA | LUAD patient datasets | links FOXM1 expression to T cell and myeloid cell profiles | paper

    Core Findings and Why They Matter

    The study demonstrates that FOXM1 expression is significantly elevated in LUAD tissues relative to controls, with higher FOXM1 levels correlating with poorer patient prognosis (source: paper). Functional experiments revealed that FOXM1 knockdown reduces LUAD cell proliferation and enhances apoptosis, underscoring its oncogenic role. Crucially, the ceRNA network analysis identified has-miR-204-5p as a direct regulator of FOXM1, while DGCR5 was shown not to interact with miR-204-5p in this context. An additional layer of complexity emerged with the demonstration of physical and regulatory interplay between FOXM1 and estrogen receptor 1 (ERα). This supports a model in which estrogen receptor signaling intersects with FOXM1-driven tumor biology—a finding with significant implications for both biomarker development and therapeutic targeting. Notably, patients with low FOXM1 expression showed increased sensitivity to immune checkpoint blockade (anti-PD1 and anti-CTLA4), suggesting that FOXM1 status could inform personalized immunotherapy strategies.

    Comparison with Existing Internal Articles

    Recent internal resources, such as “PPT (Propyl Pyrazole Triol): Precision Tools for ERα Signaling Assays” (link), emphasize the experimental value of selective ERα agonists like PPT in dissecting estrogen receptor signaling networks. The present study’s findings intersect with this paradigm by revealing that ERα is not merely a downstream effector but a physically interacting partner in the regulatory network involving FOXM1. Likewise, “Selective ERα Agonism with PPT: A Precision Paradigm for ...” (link) discusses how PPT’s selectivity enables mechanistic studies in hormone-driven cancers, including LUAD. The reference paper adds granularity to this discussion by identifying specific ceRNA and miRNA interactions upstream of ERα activity, thereby expanding the mechanistic canvas for estrogen receptor alpha agonist research.

    Limitations and Transferability

    While the reference study integrates extensive bioinformatic and experimental data, several limitations must be acknowledged:
    • Sample Diversity: Most analyses are derived from bulk tissue datasets, which may obscure cell-type-specific interactions within the tumor microenvironment (source: paper).
    • In Vivo Validation: The functional assays are limited to in vitro models; further in vivo studies are required to confirm the ceRNA network's role in LUAD progression and therapy response.
    • Causal Mechanisms: While physical interaction between FOXM1 and ERα is demonstrated, the causal directionality and broader signaling consequences remain to be elucidated.
    • Immunotherapy Response: The link between FOXM1 expression and immunotherapeutic sensitivity is based on correlative analyses and warrants prospective clinical validation.
    Transferability to other cancer types or patient populations should be approached with caution, as the regulatory networks described may be context-dependent.

    Research Support Resources

    For researchers aiming to dissect ERα-mediated gene expression and estrogen receptor signaling in LUAD or related models, selective chemical probes are indispensable. PPT (Propyl Pyrazole Triol), a potent, selective ERα agonist (SKU B6735) from APExBIO can be incorporated into cellular and in vivo assays to selectively activate estrogen receptor alpha, facilitating the mechanistic study of ERα’s influence in cancer biology and gene regulation workflows (source: workflow_recommendation). For practical assay guidance and protocol optimization, consult recent internal resources such as “Optimizing ERα Signaling Assays with PPT” (link), which provides evidence-based recommendations for experimental design in hormone receptor research.